Study of Sirolimus in IgG4-related Disease
IgG4-related DiseasegG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al. Glucocorticoids are the first-line agents for the treatment of IgG4-RD, however, in order to maintain long-term disease stability and avoid disease relapse, glucocorticoids maintenance therapy should last for a long period, which may induce various glucocorticoid-associated adverse reactions. Sirolimus plays dual roles in inhibiting lymphocyte activation and fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good potential treatment option for IgG4-RD. Therefore, we conducted this single-arm clinical trial on patients with IgG4-RD to determine the efficacy and safety of sirolimus.
Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related...
Immunoglobulin E-Mediated Food AllergyImmunoglobulin G4-Related Disease2 moreThe aim of this study is to analyze a population with symptoms associated with adverse reactions to foodstuffs (ARFS). To determine the levels of food-specific immunoglobulin G4 (IgG4) and immunoglobulin E (IgE) antibody reactions (AbR).
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
IgG4 Related DiseaseThis study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
National Registry of IgG4-RD in China
IgG4-Related DiseaseThe aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China. Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around China. A online database system has been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IgG4-RD patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.
Meir Medical Center Rheumatologic Biobank
Rheumatoid ArthritisLupus Erythematosus4 moreSerum, synovial fluid and skin biopsies from patients will be collected to the biobank with rheumatoid diseases. These samples will later be used for clinical and basic research, following approval of each specific study by the IRB. The investigators intend to extract protein, DNA and RNA from each sample.
A Prospective Cohort Study of IgG4RD in China
IgG4-related DiseaseThis is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
Safety and Efficacy of Abatacept in IgG4-Related Disease
IgG4-related DiseaseThis is a Phase 2, single center, proof of concept clinical trial in subjects with active IgG4-Related Disease (IgG4-RD). Approximately 10 subjects with active IgG4-RD will be enrolled into this study. Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks).
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease...
IgG4-RDThe purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
Leflunomide for Maintenance of Remission in IgG4 Related Disease
Immunoglobulin G4 Related Sclerosing DiseaseThe study has been designed as a 12-month, open-label, randomized, controlled study comparing the use of prednisone mono-therapy and prednisone and leflunomide combination therapy in treating patients with IgG4-related disease.
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Immunoglobulin G Subclass 4 Related DiseaseIgG4-related Disease3 moreAmong persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?